Litigation Details for Apple Inc. v. Masimo Corporation (D. Del. 2022)

« Back to Dashboard

Apple Inc. v. Masimo Corporation (D. Del. 2022)

Docket		Date Filed	2022-10-20
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	Plaintiff	Referred To	Jennifer L. Hall
Patents	10,016,403; 11,040,018; 11,040,023; 12,005,052
Link to Docket	External link to docket

Details for Apple Inc. v. Masimo Corporation (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-20				External link to document

Apple Inc. v. Masimo Corporation, 1:22-cv-01377: Litigation Summary and Patent Analysis

Last updated: August 19, 2026

Apple Inc. v. Masimo Corporation, No. 1:22-cv-01377-JLH, was a Delaware trade-secret, contract, and patent dispute arising from Masimo’s entry into the smartwatch market and Apple’s blood-oxygen monitoring technology. Apple alleged that former Apple engineers misappropriated confidential information and helped Masimo develop competing wearable products. Masimo counterclaimed that Apple infringed Masimo pulse-oximetry patents.

The Delaware jury trial produced a narrow Apple victory: Masimo’s products were found to infringe Apple design patents, resulting in a $250,000 award. The jury rejected the principal trade-secret claims and did not award Apple the commercial relief that would have materially restricted Masimo’s smartwatch business. The dispute also ran in parallel with a separate U.S. International Trade Commission proceeding that created the principal near-term commercial risk for Apple Watch sales.

What is Apple v. Masimo, 1:22-cv-01377?

Apple filed the action in the U.S. District Court for the District of Delaware in October 2022. The case was assigned to Judge Jennifer L. Hall.

Apple’s claims centered on four theories:

1. Misappropriation of trade secrets.
2. Breach of confidentiality and employment-related obligations.
3. Unfair competition and related business torts.
4. Infringement of Apple design patents covering aspects of Apple Watch products.

Apple argued that Masimo recruited former Apple employees, including engineers with knowledge of Apple’s wearable health technology, and used that information to accelerate development of Masimo’s W1 and Freedom smartwatch products.

Masimo denied misappropriation and asserted that Apple infringed Masimo patents covering pulse-oximetry systems, signal processing, and wearable blood-oxygen measurement. The counterclaims linked the Delaware action to Masimo’s broader campaign against Apple’s blood-oxygen functionality.

Case profile

Item	Details
Case	Apple Inc. v. Masimo Corporation
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:22-cv-01377-JLH
Filing date	October 2022
Plaintiff	Apple Inc.
Defendant and counterclaimant	Masimo Corporation
Core technology	Smartwatches, pulse oximetry, blood-oxygen monitoring
Principal Apple claims	Trade-secret misappropriation, contract-related claims, design-patent infringement
Principal Masimo claims	Patent infringement involving pulse-oximetry technology
Trial result	Jury found infringement of Apple design patents and awarded $250,000
Parallel proceeding	U.S. International Trade Commission Investigation No. 337-TA-1276

What did Apple allege against Masimo?

Apple alleged that Masimo used former Apple employees to obtain confidential information concerning wearable health monitoring and Apple Watch development. The complaint identified former Apple employees who later joined Masimo and alleged that Masimo’s hiring activity was part of a coordinated effort to compete with Apple in the smartwatch market.

The trade-secret theory was commercially more important than the design-patent claims. A successful trade-secret verdict could have supported substantial damages, exemplary damages, attorneys’ fees, and injunctive relief. Apple also sought relief directed at Masimo’s alleged use of confidential information in developing its wearable products.

Apple’s design-patent claims covered the appearance of Apple Watch-related products. Those claims were narrower than the trade-secret allegations because they focused on ornamental design elements rather than the underlying blood-oxygen technology.

What products were implicated?

The dispute involved Masimo’s W1 smartwatch, Freedom smartwatch, and related charger or accessory products. Apple argued that those products copied protected design elements associated with Apple Watch products.

The technology dispute also concerned Masimo’s health-monitoring products and Apple Watch models equipped with blood-oxygen monitoring. The design-patent claims and the pulse-oximetry patent claims addressed different forms of intellectual property:

• Apple’s design patents concerned product appearance.
• Masimo’s patents concerned functional pulse-oximetry technology.
• Apple’s trade-secret claims concerned confidential technical and business information.

This separation mattered at trial. A finding that a Masimo product copied Apple’s exterior design did not establish that Masimo misappropriated Apple’s technical information.

What did Masimo allege against Apple?

Masimo’s counterclaims alleged that Apple infringed Masimo patents covering pulse-oximetry systems used in Apple Watch products. Masimo’s technology measures blood oxygen by emitting light into tissue and analyzing the returning signals. The claims included hardware, signal-processing, and system-level elements.

Masimo’s patent claims were also asserted in the ITC. The ITC proceeding became the more consequential forum for Apple because the commission can issue exclusion orders that restrict importation of infringing products into the United States.

The Delaware case involved damages and equitable relief. The ITC case involved importation and exclusion remedies. The two proceedings therefore created different risk profiles:

Issue	Delaware district court	U.S. ITC
Primary remedy	Damages, injunctions, declarations	Exclusion order and cease-and-desist order
Jury trial	Available	No jury
Importation requirement	Not required	Required
Effect on Apple Watch sales	Usually indirect unless injunction issues	Potentially immediate
Patent validity and infringement	Decided by court or jury	Decided by administrative law judge and commission

What was the Apple v. Masimo jury verdict?

The Delaware jury found that Masimo infringed two Apple design patents through its W1 and Freedom products and associated charger. The jury awarded Apple $250,000.

The award was limited. Apple did not obtain the large trade-secret damages award that would have followed a finding of willful misappropriation. The verdict also did not produce a broad injunction stopping Masimo from selling its wearable products.

Public reporting on the verdict described the award as the amount Apple requested for the design-patent claims. The result gave Apple a legal win on product appearance but did not establish that Masimo stole Apple’s confidential technology or that Masimo’s entire smartwatch product line was unlawfully derived from Apple technology.

What claims did Apple lose?

The jury rejected Apple’s central trade-secret theory. That outcome reduced the case’s value as a precedent for restricting employee movement between technology companies and weakened Apple’s ability to claim that Masimo’s product development was based on Apple confidential information.

The result also limited damages exposure. Trade-secret misappropriation can support actual damages, unjust enrichment, exemplary damages, and attorneys’ fees. A design-patent verdict based on a limited number of products produced a much smaller economic result.

What was the relationship to the Masimo ITC case?

Masimo separately pursued Apple at the ITC in Investigation No. 337-TA-1276. The ITC found that Apple infringed Masimo patents related to pulse oximetry and issued a limited exclusion order covering certain Apple Watch models.

The U.S. Trade Representative declined to veto the exclusion order. Apple temporarily halted U.S. sales of affected Apple Watch models in December 2023. Apple later pursued a software-based workaround and resumed sales, while continuing to challenge the ITC determination in the Federal Circuit.

The ITC dispute was commercially more important to Apple than the $250,000 Delaware verdict. Apple Watch is a major Apple product category, and a sales interruption affects revenue, customer conversion, retail distribution, and the use of the Apple Watch as an entry point to Apple’s broader device ecosystem.

The two proceedings also produced asymmetric outcomes:

Litigation track	Apple’s position	Masimo’s position	Commercial effect
Delaware district court	Apple won limited design-patent claims	Masimo avoided major trade-secret liability	Limited direct financial effect
ITC Investigation No. 337-TA-1276	Apple faced exclusion risk	Masimo obtained an exclusion order	Direct risk to Apple Watch imports and sales
Federal Circuit appeal	Apple challenged ITC findings	Masimo defended exclusion remedy	Ongoing patent and product-design risk

What patents protect Apple Watch against Masimo?

The Delaware case involved Apple design patents rather than the core functional patents asserted by Masimo in the ITC.

Design patents protect the ornamental appearance of an article of manufacture. They can cover contours, housing geometry, display arrangements, or visual combinations shown in the patent drawings. Their protection is product-specific and narrower than utility-patent protection.

For Apple, the design-patent claims offered three strategic advantages:

1. They did not require proof that Masimo copied Apple’s technical architecture.
2. They could be applied directly to the appearance of competing wearable products.
3. They created a litigation path even after the trade-secret claims failed.

Their limitations were equally significant. Design patents generally do not block an entire product category. A competitor can redesign the accused exterior and continue selling substantially the same technical product.

How strong was Apple’s trade-secret case?

The jury result indicates that Apple did not establish the required elements of trade-secret misappropriation at trial. The principal evidentiary issues in this type of case are whether:

• The information qualified as a trade secret.
• Apple took reasonable measures to protect it.
• The former employees acquired the information improperly.
• Masimo used the information in developing the accused products.
• The alleged information was sufficiently specific and technically connected to the products.

Employee movement alone does not prove trade-secret misappropriation. Apple needed to connect alleged confidential information to Masimo’s conduct and product development. The jury’s rejection of the trade-secret theory suggests that the evidence did not establish that connection to the required standard.

The verdict also reduces the precedential value of the case for future employee-hiring disputes. Apple obtained a design-patent result, but not a broad finding that hiring former employees with wearable-technology expertise amounted to unlawful use of Apple trade secrets.

What is the patent strength of the competing estates?

Apple’s position

Apple’s relevant strength was commercial scale, product integration, and a broad portfolio covering device design, user interfaces, sensors, software, and manufacturing. In this case, the successful design-patent claims showed that Apple could use its portfolio to challenge the physical appearance of competing wearables.

Apple’s weakness was claim concentration. Design patents do not protect the functional pulse-oximetry methods that drove the ITC dispute. Apple therefore needed separate utility-patent coverage to defend the blood-oxygen feature itself.

Masimo’s position

Masimo’s strongest position was its specialized pulse-oximetry portfolio. The ITC findings gave Masimo leverage against Apple because the remedy reached imported products. Masimo’s patents were directed to technology in its core medical-monitoring field rather than to general smartwatch appearance.

Masimo’s weakness was the limited Delaware outcome. The jury did not impose substantial liability on Apple in the district-court case, and Apple’s design-patent verdict did not eliminate Masimo’s ability to redesign its products.

Patent category	Apple	Masimo
Product design	Strong claim against selected Masimo wearables	Vulnerable to redesign
Pulse-oximetry functionality	Defendant-side exposure in ITC	Stronger litigation leverage
Trade secrets	Alleged misappropriation, unsuccessful at trial	Avoided major damages
Injunctive leverage	Limited Delaware result	ITC exclusion remedy
Commercial moat	Ecosystem, distribution, brand, device integration	Medical-monitoring expertise and patent specialization

Are there Paragraph IV challenges or generic-entry issues?

No conventional Paragraph IV generic challenge is central to this litigation. Paragraph IV litigation concerns an abbreviated new drug application and Orange Book-listed patents. Apple Watch and Masimo wearables are regulated as medical or consumer devices, not as small-molecule drugs approved through the ANDA pathway.

The relevant competitive-entry risks are therefore different:

• Design-around risk for wearable housings and interfaces.
• Patent litigation over sensor architecture and signal processing.
• Import exclusion risk at the ITC.
• Regulatory changes affecting blood-oxygen functionality.
• Product redesign and software workarounds.
• Licensing or supply arrangements for pulse-oximetry components.

There is no Orange Book listing, FDA small-molecule exclusivity period, or biosimilar pathway associated with the Delaware action.

What was the FDA regulatory status?

The dispute was not an FDA drug-exclusivity case. Apple Watch blood-oxygen functionality and Masimo’s wearable products occupy a medical-device and consumer-electronics regulatory environment.

Masimo markets regulated medical-monitoring products, while Apple has incorporated blood-oxygen functionality into Apple Watch products. Regulatory classification, device clearance, labeling, and intended use can affect the technical and commercial scope of the products, but FDA approval does not resolve patent infringement.

The ITC remedy demonstrated the distinction between regulatory authorization and patent freedom to operate. A product may be lawfully marketed from an FDA perspective and still face exclusion based on patent infringement.

What licensing deals or settlement agreements resolved the dispute?

The public record associated with the Delaware verdict did not produce a broad cross-license between Apple and Masimo. The litigation proceeded through trial, and the principal commercial developments involved the ITC exclusion order, Apple’s sales suspension, software changes, and appellate proceedings.

The absence of a comprehensive public settlement means each company retained substantial freedom to pursue separate products, patent enforcement, and redesign strategies. A negotiated license would have been commercially significant because Masimo’s patents targeted Apple’s blood-oxygen functionality while Apple’s design patents targeted Masimo’s wearable products.

What generic launch or competitor-entry scenarios exist?

The case does not create a traditional generic-launch event. The relevant scenarios are product-specific.

Masimo launch scenario

Masimo can continue competing if it modifies the external design of accused products and avoids the scope of Apple’s design patents. Its greater risk remains functional patent enforcement by Apple or other competitors in the wearable market.

Apple launch scenario

Apple can continue selling Apple Watch products if it avoids infringement of Masimo’s pulse-oximetry claims, obtains a license, prevails on appeal, or implements a technically and commercially acceptable workaround.

Third-party competitor scenario

Competitors may benefit from the dispute if they offer blood-oxygen monitoring without infringing either company’s patent claims. The litigation increases the value of independent sensor designs, alternative signal-processing techniques, and differentiated industrial design.

What revenue exposure did the litigation create?

The Delaware damages award was immaterial relative to Apple’s company-wide revenue and modest relative to the Apple Watch business. The principal revenue exposure came from the ITC exclusion order, which could restrict sales of affected Apple Watch models in the United States.

For Masimo, the litigation affected a strategic expansion into consumer wearables. An adverse design-patent injunction or redesign obligation could increase development costs and slow distribution. The $250,000 verdict itself did not create a material financial burden, but continued litigation could impose legal expense, redesign cost, channel disruption, and investor scrutiny.

The commercial risk was therefore asymmetric:

• Apple faced high product-level exposure from the ITC case.
• Masimo faced strategic and product-design exposure from Apple’s Delaware claims.
• Neither company received a broad final judgment eliminating the other from the wearable market.

What is the current litigation significance of Apple v. Masimo?

The Delaware action is best understood as a limited design-patent victory for Apple within a broader technology and market-access conflict. The verdict did not validate Apple’s trade-secret allegations, did not award substantial damages, and did not remove Masimo from the smartwatch market.

Masimo’s ITC victory created the more significant operational pressure because it implicated Apple Watch imports. The combined proceedings show how companies can use different forums against the same competitor:

• District courts provide damages trials and broader fact development.
• The ITC offers rapid import remedies.
• Design patents can target product appearance.
• Utility patents can target sensor and software functionality.
• Trade-secret claims can address employee mobility and confidential development information.

Key Takeaways

• Apple v. Masimo, No. 1:22-cv-01377-JLH, was filed in Delaware in October 2022.
• Apple alleged trade-secret misappropriation, contract-related violations, and design-patent infringement.
• Masimo counterclaimed that Apple infringed pulse-oximetry patents.
• The Delaware jury found Masimo’s W1 and Freedom products and related charger infringed Apple design patents.
• Apple received a $250,000 award.
• The jury rejected Apple’s central trade-secret case.
• The Delaware verdict did not materially restrict Masimo’s smartwatch business.
• The ITC proceeding, Investigation No. 337-TA-1276, created the larger near-term risk for Apple Watch sales.
• The dispute did not involve Paragraph IV litigation, Orange Book patents, or biosimilar entry.
• No broad public cross-license or settlement resolved the underlying technology conflict.
• The principal freedom-to-operate issue remains Masimo’s pulse-oximetry patent estate and Apple’s ability to design around, invalidate, license, or defeat those claims.

FAQs

Did Apple win or lose Apple v. Masimo?

Apple won limited design-patent claims and received $250,000. It did not prevail on its principal trade-secret misappropriation theory.

Did Masimo copy the Apple Watch?

The jury found infringement of Apple design patents by specified Masimo products. That finding did not establish that Masimo copied Apple’s confidential technical information or copied the Apple Watch as a whole.

Can Masimo still sell its W1 and Freedom smartwatches?

The Delaware verdict did not impose a broad sales ban. Continued sales depend on the scope of post-trial relief, any redesign, and the separate ITC and appellate proceedings.

Why was the Apple Watch blood-oxygen feature disabled?

Apple disabled the feature in certain U.S. Apple Watch models after the ITC found infringement of Masimo pulse-oximetry patents and issued an exclusion order affecting Apple Watch imports.

Is Apple v. Masimo relevant to wearable-device licensing?

Yes. The case demonstrates that wearable-device licensing may need to address separate rights for industrial design, sensor hardware, signal processing, software, employee-developed know-how, and importation.

References

1. Apple Inc. v. Masimo Corp., No. 1:22-cv-01377-JLH, Complaint (D. Del. Oct. 2022).

2. U.S. International Trade Commission. (2023). Certain light-based physiological measurement devices and components thereof, Inv. No. 337-TA-1276, Commission Opinion and Limited Exclusion Order.

3. U.S. Court of Appeals for the Federal Circuit. (2024). Masimo Corp. v. Apple Inc., appeal concerning Investigation No. 337-TA-1276.

4. Reuters. (2024). Apple wins $250,000 in patent trial against Masimo over smartwatches.

5. U.S. Patent and Trademark Office. (n.d.). Design patent examination guidance and patent term information.